Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Shares Outstanding (Weighted Average) (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Shares Outstanding (Weighted Average) for 10 consecutive years, with $55.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 3.22% year-over-year to $55.9 million, compared with a TTM value of $55.9 million through Sep 2025, up 3.22%, and an annual FY2024 reading of $54.0 million, up 2.53% over the prior year.
  • Shares Outstanding (Weighted Average) was $55.9 million for Q3 2025 at Spero Therapeutics, roughly flat from $56.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $56.0 million in Q2 2025 and bottomed at $29.4 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $45.0 million, with a median of $52.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 61.09% in 2023, then grew 1.9% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $30.9 million in 2021, then rose by 21.65% to $37.6 million in 2022, then skyrocketed by 40.22% to $52.7 million in 2023, then increased by 2.53% to $54.0 million in 2024, then rose by 3.38% to $55.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for SPRO at $55.9 million in Q3 2025, $56.0 million in Q2 2025, and $55.4 million in Q1 2025.